ClinicalTrials.gg
CompletedNCT03340454Updated Jul 3, 2024Results posted

Patient-Centered Cancer Prevention In Chinese Americans

An interventional study of Test-and-treat EHR-CHW intervention and Usual care of EHR-only intervention in H. Pylori Infection, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study will assess the efficacy, adoption, and impact of an integrated intervention to improve adherence to recommended stomach cancer prevention guidelines (H. pylori test-and-treat) for at-risk Chinese Americans in NYC. The integrated multifaceted theory-based intervention involves: 1) a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies; and 2) a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability. Using a 2-arm randomized controlled trial (RCT) design, > 144 Chinese American patients across NYC safety net hospital endoscopy clinics and primary health centers will participate.

02

Conditions studied

  • H. Pylori Infection

Keywords

  • H. pylori
  • H. pylori infection
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,421 studies on the registry; 254 are open to participants now.

Of its 231 completed or terminated interventional studies of FDA-regulated products, 195 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • self identifies as Chinese American
  • is an outpatient aged 21 years and older (adult)
  • plans to continue to live in the region during the next 12 months;
  • is willing to be randomized to either treatment or control groups
  • has a confirmed diagnosis of H. pylori infection by at least one of the following methods: C-urea breath test, histology, rapid urease test or bacterial culture, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test.

Exclusion criteria

Exclusion Criteria:

  • advanced chronic disease that would not allow the patient to complete follow-up or attend visits;
  • allergy to any of the study drugs;
  • pregnancy or currently breastfeeding
  • taking antibiotics or bismuth salts within 2 weeks before the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Active comparator
    Health systems-level intervention

    using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;

    Other: Test-and-treat EHR-CHW intervention

  • Active comparator
    CHW-led patient navigation program

    a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability

    Other: Usual care of EHR-only intervention

Interventions

  • OtherTest-and-treat EHR-CHW intervention

    a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies

  • OtherUsual care of EHR-only intervention

    a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Eradication of H. Pylori (ITT)

    Measured using breath ammonia measurement, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test. Data extracted from patient EHR. Includes positive results for those with self-reported or missing results.

    Time frame: Up to Month 3-Post Treatment

Secondary outcomes

  1. Number of Participants With Eradication of H. Pylori (Clinically Confirmed)

    Measured using breath ammonia measurement, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test. Data extracted from patient EHR.

    Time frame: Up to Month 3-Post Treatment

  2. Change in Ottawa Decision Self-Efficacy Scale Score From Baseline to 6 Months

    Participants completed the Ottawa Decision Self-Efficacy Scale, which assessed participants' confidence in making an informed choice, at baseline and 6-month follow-up. The scale consists of 11 questions on a 5-point Likert scale from 0 (not at all confident) to 4 (very confident). The raw score is the sum of responses. The raw score is converted to a standardized total score that ranges from 0 to 100; higher total scores indicate greater decision self-efficacy.

    Time frame: Baseline, Month 6

  3. Change in Medication Adherence Report Scale (MARS-5) Score From Baseline to Month 6

    Participants completed the MARS-5 self-assessment of medication adherence at baseline and 6-month follow-up. One item assessed unintentional non-adherence, while four items assessed intentional non-adherence. Participants indicated how often each statement applied to them in the past month on a 5-point Likert scale (1=always, 2=often, 3=sometimes, 4=rarely, 5=never), resulting in a total score ranging from 5 to 25. Adherence is defined as a score of 25.

    Time frame: Baseline, Month 6

  4. Change in Stomach Cancer Knowledge Between Baseline and 6-months

    Participants were asked about associations with the risk of getting stomach cancer (alcohol, spicy food, stress, family history, h. pylori infection, smoking, salty food, being physically inactive, pickled food, food high in sugar). True or false was chosen. Variables were recoded to correct (1) and incorrect (0), and summed for a final score (0-10, 10=highest knowledge)

    Time frame: Baseline, Month 6

  5. Change in H. Pylori Knowledge Between Baseline and 6-months

    Participants were asked about associations with h. pylori (blood, untreated/contaminated water, rats, mosquitoes, contaminated food, vomit, poor sanitation). True or false was chosen. Variables were recoded to correct (1) and incorrect (0), and summed for a final score (0-7, 7=highest knowledge)

    Time frame: Baseline, Month 6

  6. Change in PROMIS Global Physical Health T-Score Between Baseline and 6-months

    Participants completed the PROMIS Global Physical Health Scale, which assessed participants' physical health, at baseline and 6-month follow-up. Four questions assessed global physical health. Three questions were administered using five-category response scales, and one item used a response scale of 0-10 that was recoded to five categories. Responses are recoded into t-scores, which rescales the raw sum score into a standardized score from 0-100, with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the concept being measured.

    Time frame: Baseline, Month 6

  7. Change in PROMIS Global Mental Health T-Score Between Baseline and 6-months

    Participants completed the PROMIS Global Mental Health Scale, which assessed participants' mental health, at baseline and 6-month follow-up. Four questions assessed global mental health, and all were administered using five-category response scales. Responses are recoded into t-scores, which rescales the raw sum score into a standardized score from 0-100, with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the concept being measured.

    Time frame: Baseline, Month 6

07

Results

Posted Jul 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneHealth Systems-level InterventionCHW-led Patient Navigation Program
Started6768
Completed6764
Not completed04
Withdrew: Lost to follow-up04

Outcome measures

PrimaryNumber of Participants With Eradication of H. Pylori (ITT)

Measured using breath ammonia measurement, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test. Data extracted from patient EHR. Includes positive results for those with self-reported or missing results.

Time frame:
Up to Month 3-Post Treatment
Reported as:
Count of participants · Participants
Number of Participants With Eradication of H. Pylori (ITT)
ParticipantsHealth Systems-level InterventionCHW-led Patient Navigation Program
Number of Participants With Eradication of H. Pylori (ITT)4954
SecondaryNumber of Participants With Eradication of H. Pylori (Clinically Confirmed)

Measured using breath ammonia measurement, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test. Data extracted from patient EHR.

Time frame:
Up to Month 3-Post Treatment
Reported as:
Count of participants · Participants
Number of Participants With Eradication of H. Pylori (Clinically Confirmed)
ParticipantsHealth Systems-level InterventionCHW-led Patient Navigation Program
Number of Participants With Eradication of H. Pylori (Clinically Confirmed)4954
SecondaryChange in Ottawa Decision Self-Efficacy Scale Score From Baseline to 6 Months

Participants completed the Ottawa Decision Self-Efficacy Scale, which assessed participants' confidence in making an informed choice, at baseline and 6-month follow-up. The scale consists of 11 questions on a 5-point Likert scale from 0 (not at all confident) to 4 (very confident). The raw score is the sum of responses. The raw score is converted to a standardized total score that ranges from 0 to 100; higher total scores indicate greater decision self-efficacy.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change in Ottawa Decision Self-Efficacy Scale Score From Baseline to 6 Months
score on a scaleHealth Systems-level InterventionCHW-led Patient Navigation Program
Change in Ottawa Decision Self-Efficacy Scale Score From Baseline to 6 Months5 ± 13.595.7 ± 11.77
SecondaryChange in Medication Adherence Report Scale (MARS-5) Score From Baseline to Month 6

Participants completed the MARS-5 self-assessment of medication adherence at baseline and 6-month follow-up. One item assessed unintentional non-adherence, while four items assessed intentional non-adherence. Participants indicated how often each statement applied to them in the past month on a 5-point Likert scale (1=always, 2=often, 3=sometimes, 4=rarely, 5=never), resulting in a total score ranging from 5 to 25. Adherence is defined as a score of 25.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change in Medication Adherence Report Scale (MARS-5) Score From Baseline to Month 6
score on a scaleHealth Systems-level InterventionCHW-led Patient Navigation Program
Change in Medication Adherence Report Scale (MARS-5) Score From Baseline to Month 60.58 ± 2.690.77 ± 2.95
SecondaryChange in Stomach Cancer Knowledge Between Baseline and 6-months

Participants were asked about associations with the risk of getting stomach cancer (alcohol, spicy food, stress, family history, h. pylori infection, smoking, salty food, being physically inactive, pickled food, food high in sugar). True or false was chosen. Variables were recoded to correct (1) and incorrect (0), and summed for a final score (0-10, 10=highest knowledge)

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change in Stomach Cancer Knowledge Between Baseline and 6-months
score on a scaleHealth Systems-level InterventionCHW-led Patient Navigation Program
Change in Stomach Cancer Knowledge Between Baseline and 6-months1.58 ± 2.253.25 ± 2.9
SecondaryChange in H. Pylori Knowledge Between Baseline and 6-months

Participants were asked about associations with h. pylori (blood, untreated/contaminated water, rats, mosquitoes, contaminated food, vomit, poor sanitation). True or false was chosen. Variables were recoded to correct (1) and incorrect (0), and summed for a final score (0-7, 7=highest knowledge)

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change in H. Pylori Knowledge Between Baseline and 6-months
score on a scaleHealth Systems-level InterventionCHW-led Patient Navigation Program
Change in H. Pylori Knowledge Between Baseline and 6-months1.03 ± 22.56 ± 2.5
SecondaryChange in PROMIS Global Physical Health T-Score Between Baseline and 6-months

Participants completed the PROMIS Global Physical Health Scale, which assessed participants' physical health, at baseline and 6-month follow-up. Four questions assessed global physical health. Three questions were administered using five-category response scales, and one item used a response scale of 0-10 that was recoded to five categories. Responses are recoded into t-scores, which rescales the raw sum score into a standardized score from 0-100, with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the concept being measured.

Time frame:
Baseline, Month 6
Reported as:
Mean · T-score
Change in PROMIS Global Physical Health T-Score Between Baseline and 6-months
T-scoreHealth Systems-level InterventionCHW-led Patient Navigation Program
Change in PROMIS Global Physical Health T-Score Between Baseline and 6-months-1.1 ± 2.711.27 ± 8.27
SecondaryChange in PROMIS Global Mental Health T-Score Between Baseline and 6-months

Participants completed the PROMIS Global Mental Health Scale, which assessed participants' mental health, at baseline and 6-month follow-up. Four questions assessed global mental health, and all were administered using five-category response scales. Responses are recoded into t-scores, which rescales the raw sum score into a standardized score from 0-100, with a mean of 50 and a standard deviation of 10. Higher scores indicate more of the concept being measured.

Time frame:
Baseline, Month 6
Reported as:
Mean · T-score
Change in PROMIS Global Mental Health T-Score Between Baseline and 6-months
T-scoreHealth Systems-level InterventionCHW-led Patient Navigation Program
Change in PROMIS Global Mental Health T-Score Between Baseline and 6-months0.69 ± 6.843.13 ± 6.07

Adverse events

Collected over 6 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Health Systems-level Intervention0/67 (0%)0/67 (0%)0/67 (0%)
CHW-led Patient Navigation Program0/68 (0%)0/68 (0%)0/68 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Health Systems-level InterventionCHW-led Patient Navigation ProgramTotal
Mean44 (23 to 81)42 (25 to 69)43.5 (23 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Health Systems-level InterventionCHW-led Patient Navigation ProgramTotal
Female363470
Male313061
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Health Systems-level InterventionCHW-led Patient Navigation ProgramTotal
Hispanic or Latino000
Not Hispanic or Latino6764131
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Health Systems-level InterventionCHW-led Patient Navigation ProgramTotal
American Indian or Alaska Native000
Asian6764131
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Health Systems-level InterventionCHW-led Patient Navigation ProgramTotal
United States6764131
08

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 9, 2023

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03340454
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Aug 15, 2018
Primary completion
Jun 15, 2023
Completion
Jun 15, 2023
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Study contacts

Simona Kwon, DrPH,MPH
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion